论文部分内容阅读
目的探讨非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)组织中Raf激酶抑制蛋白(Raf Kinase Inhibitor Protein,RKIP)和果蝇Zeste基因增强子人类同源物(Enhancer of Zeste Homolog,EZH2)的表达及其与临床病理特征的关系。方法应用免疫组织化学方法检测84例肺癌组织及相应的癌旁正常肺组织中RKIP与EZH2蛋白的表达情况,分析两者与肺癌临床病理学参数的关系。结果肺癌组织中RKIP的阳性表达率为36.90%(31/84),低于癌旁正常肺组织63.10%(53/84),差异有统计学意义(χ2=11.524,P<0.05);EZH2的阳性表达率为60.71%(51/84),高于癌旁正常肺组织39.29%(33/84),差异有统计学意义(χ2=7.714,P<0.05)。其表达水平与肺癌的分化程度、TNM分期、淋巴结转移及术后生存时间有明显关系;RKIP蛋白与EZH2蛋白的表达水平呈负相关(r=-0.446,P<0.05)。结论RKIP与EZH2在肺癌的发生、发展中起重要作用,RKIP的低表达以及EZH2的过表达,促进了肺癌细胞的侵袭和转移。
Objective To investigate the effects of Raf Kinase Inhibitor Protein (RKIP) and Enhancer of Zeste Homolog (EZH2) in non-small cell lung cancer (NSCLC) Expression and Its Relationship with Clinicopathological Features. Methods The expressions of RKIP and EZH2 protein in 84 lung cancer tissues and corresponding normal lung tissues were detected by immunohistochemistry. The relationship between them and clinicopathological parameters of lung cancer was analyzed. Results The positive expression rate of RKIP in lung cancer was 36.90% (31/84), which was lower than that in normal lung tissue (63.10%, 53/84) (χ2 = 11.524, P <0.05) The positive expression rate was 60.71% (51/84), which was higher than that in the adjacent normal lung tissues (39.29%, 33/84). The difference was statistically significant (χ2 = 7.714, P <0.05). The expression level of RKIP was significantly correlated with the differentiation of lung cancer, TNM stage, lymph node metastasis and postoperative survival time. The expression of RKIP protein was negatively correlated with the expression of EZH2 protein (r = -0.446, P <0.05). Conclusion RKIP and EZH2 play an important role in the development and progression of lung cancer. The low expression of RKIP and overexpression of EZH2 promote the invasion and metastasis of lung cancer cells.